<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01882530</url>
  </required_header>
  <id_info>
    <org_study_id>130505A-32</org_study_id>
    <nct_id>NCT01882530</nct_id>
  </id_info>
  <brief_title>Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia.</brief_title>
  <acronym>OCTOPUS</acronym>
  <official_title>Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of different analgesic drugs and/or analgesia techniques is part of the
      standard management of postoperative analgesia. The analysis of the literature reveals a lack
      of comparison of the associations of non-opioid analgesic (NOA) with morphine for
      postoperative analgesia.

      The objectives of this study are :

        -  comparing the morphine sparing effect of different combination of 3 NOA (paracetamol,
           nefopam, ketoprofen) for postoperative analgesia.

        -  determining whether the morphine-sparing effect is associated with or without a
           reduction in the incidence of morphine side effects.

        -  evaluating the effects of NOA on postoperative hyperalgesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since the description of the concept of balanced analgesia in the early 90's, the combination
      of different analgesic drugs and/or analgesia techniques is part of the standard management
      of postoperative analgesia. A recent survey conducted in France by Fletcher et al. showed
      that patients often received one or more NOA associated with an opioid. The benefit and risk
      of the use of opioids associated with NOA were recently reassessed as part of a formal
      recommendation of experts and detailed in a recent review. The analysis of the literature
      reveals a lack of comparison of the combinations of NOA with morphine for postoperative
      analgesia. For example, paracetamol and morphine in combination does not always allow a
      significant morphine-sparing effect compared with morphine alone and does not reduce the
      incidence of morphine side effects. A number of definitive answers has therefore yet to be
      found: Does NOA -morphine association allow an effective morphine-sparing effect? Is there an
      interest in prescribing several NOAs in association? If yes, what are the most interesting
      combinations in terms of morphine-sparing effect and safety?

      Another question concerns the effects of NOA on postoperative hyperalgesia. This
      hyperalgesia, which results from surgery-related inflammation, is increased by consumption of
      morphine and not only contributes to the overall experience of postoperative pain but also to
      the chronicisation of postoperative pain. Since in clinical practice, hyperalgesia can be
      measured using specific tools (Von Frey filament type), our study will evaluate the
      anti-hyperalgesic effects of NOA on a subgroup of patients enrolled in the centers used to
      evaluate nociceptive thresholds.

      The objectives of this study are :

        -  comparing the morphine sparing effect of different combination of 3 NOA (paracetamol,
           nefopam, ketoprofen) for postoperative analgesia.

        -  determining whether the morphine-sparing effect is associated with or without a
           reduction in the incidence of morphine side effects.

        -  evaluating the effects of NOA on postoperative hyperalgesia.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Practice on postoperative pain management changed
  </why_stopped>
  <start_date type="Actual">July 23, 2013</start_date>
  <completion_date type="Actual">January 16, 2016</completion_date>
  <primary_completion_date type="Actual">January 16, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption (mg), accumulated over 24 hours, measured by patient controlled analgesia (PCA).</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption (mg) measured by patient controlled analgesia (PCA).</measure>
    <time_frame>Day 2, day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects associated with morphine: nausea, vomiting, sedation, urinary retention, pruritus.</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of hyperalgesia measured using a von Frey filament expressed in cm2, 48 hours after surgery (sub-study in 3 centers).</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic pain assessed by a telephone questionnaire 3 months after surgery (sub-study in 3 centers).</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global satisfaction (measured after treatment)</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Post Operative Analgesia</condition>
  <arm_group>
    <arm_group_label>Control group C: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P: Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group N: Nefopam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K: Ketoprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group PN: paracetamol and nefopam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group PK: paracetamol and ketoprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group NK: nefopam and ketoprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group PNK: paracetamol, nefopam and ketoprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <arm_group_label>Group P: Paracetamol</arm_group_label>
    <arm_group_label>Group PN: paracetamol and nefopam</arm_group_label>
    <arm_group_label>Group PK: paracetamol and ketoprofen</arm_group_label>
    <arm_group_label>Group PNK: paracetamol, nefopam and ketoprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nefopam</intervention_name>
    <arm_group_label>Group N: Nefopam</arm_group_label>
    <arm_group_label>Group PN: paracetamol and nefopam</arm_group_label>
    <arm_group_label>Group NK: nefopam and ketoprofen</arm_group_label>
    <arm_group_label>Group PNK: paracetamol, nefopam and ketoprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoprofen</intervention_name>
    <arm_group_label>Group K: Ketoprofen</arm_group_label>
    <arm_group_label>Group PK: paracetamol and ketoprofen</arm_group_label>
    <arm_group_label>Group NK: nefopam and ketoprofen</arm_group_label>
    <arm_group_label>Group PNK: paracetamol, nefopam and ketoprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <arm_group_label>Control group C: Placebo</arm_group_label>
    <arm_group_label>Group P: Paracetamol</arm_group_label>
    <arm_group_label>Group N: Nefopam</arm_group_label>
    <arm_group_label>Group K: Ketoprofen</arm_group_label>
    <arm_group_label>Group PN: paracetamol and nefopam</arm_group_label>
    <arm_group_label>Group PK: paracetamol and ketoprofen</arm_group_label>
    <arm_group_label>Group NK: nefopam and ketoprofen</arm_group_label>
    <arm_group_label>Group PNK: paracetamol, nefopam and ketoprofen</arm_group_label>
    <other_name>All patients will receive morphine postoperatively (titration, then PCA).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults older than 18 years

          -  Receiving scheduled surgery requiring the use of a PCA to treat postoperative pain

          -  Patients with a written informed consent

          -  Patients with a written informed consent for the sub-study on hyperalgesia (patients
             in the centers concerned)

          -  Affiliate to a social security system

        Exclusion Criteria:

          -  Allergy to morphine, paracetamol, nefopam or ketoprofen or to any of their excipients

          -  Absorption of morphine and / or NOA within 24 hours before surgery

          -  Absorption of methadone within 48 hours before surgery

          -  History of epilepsy

          -  Renal insufficiency (creatinin clearance &lt;30 ml / min MDRD)

          -  Hepatic insufficiency

          -  Severe respiratory insufficiency

          -  Pregnancy or breastfeeding women

          -  History of seizures

          -  Symptomatic urethroprostatic disorders

          -  Angle-closure glaucoma

          -  Gastrointestinal, cerebrovascular or other evolving bleedings

          -  Active peptic ulcer or active gastritis

          -  Severe heart failure

          -  History of asthma triggered by taking ketoprofen or similar substances

          -  Disable adult person under guardianship

          -  Use of nitrous oxide during anesthesia protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ERIC BELLISSANT</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karine Nouette-Gaulain</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marcel Chauvin</name>
      <address>
        <city>Boulogne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawa Keita-Meyer</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dominique Fletcher</name>
      <address>
        <city>Garches</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre Albaladejo</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frédéric Aubrun</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xavier Capdevila</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hervé Bouaziz</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karim Asehnoune</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marc Raucoules</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacques Ripart</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anissa Belbachir</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emmanuel Marret</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Xavier Mazoit</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marc Beaussier</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sébastien Bloc</name>
      <address>
        <city>Quincy sous Sénart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Marc Malinovsky</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marc Gentili</name>
      <address>
        <city>St Grégoire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vincent Minville</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2013</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post operative analgesia ;</keyword>
  <keyword>Paracetamol ;</keyword>
  <keyword>Ketoprofen ;</keyword>
  <keyword>Nefopam ;</keyword>
  <keyword>Morphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
    <mesh_term>Nefopam</mesh_term>
    <mesh_term>Analgesics, Non-Narcotic</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

